Singapore Immunology Network (SIgN)
Serology testing may be fast and easy to perform, but there are still some limitations that need to be overcome, suggests Laurent Renia.
Clinicians and scientists have discovered a rare mutation that impairs the immune system, using their findings to devise treatment strategies
The presence of memory T cells in COVID-19-recovered patients hints at their importance in COVID-19 immunity.
Could there be a drug that can both treat and protect against COVID-19? The answer may be found in antibody drugs, a promising therapeutic modality against the coronavirus.
A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.
Two coronavirus experts suggest that the best way to control an outbreak may be to first understand viral biology and behavior in animals and humans.
Scientists at A*STAR have found that a mutation in SARS-CoV-2 called ∆382 leads to milder clinical outcomes, with implications for COVID-19 treatments and vaccines.
An international genetics consortium seeks to unravel the mystery of why COVID-19 infection is silent in some cases and lethal in others.
Understanding how closely related coronaviruses circulate seasonally could impact the timing of vaccination against SARS-CoV-2.
Two linear peptides identified by A*STAR researchers on the SARS-CoV-2 spike protein may improve the specificity of serological assays and show potential as vaccine candidates.
Curiox Biosystems, an A*STAR spin-off company, specializes in automated and quantitative cell analysis. Its CEO, Dr. Namyong Kim, shares the story of the company’s success.